SCHEDULE: Solas Capital Management Discloses Stake in MAIA Biotechnology

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 7.1% of MAIA Biotechnology, Inc.'s common stock as of March 31, 2026.

Summary

• Solas Capital Management, LLC and Frederick Tucker Golden have filed a Schedule 13G, indicating their beneficial ownership of MAIA Biotechnology, Inc. common stock.
• The filing reports a total of 4,297,004 shares owned, representing 7.1% of the company's outstanding common stock.
• This ownership percentage is based on 60,671,491 shares of common stock outstanding as of March 23, 2026, as stated in MAIA Biotechnology's Form 10-K.
• Solas Capital Management, LLC is identified as an investment adviser registered under the Investment Advisers Act of 1940.
• Frederick Tucker Golden is the Portfolio Manager of Solas Capital Management, LLC and has the power to exercise investment and voting discretion over the shares held by funds managed by Solas.
• Both Solas Capital Management, LLC and Frederick Tucker Golden share the power to vote and dispose of the reported shares.
• The filing explicitly states that the funds holding the securities expressly disclaim beneficial ownership, and the filing should not be construed as an admission of beneficial ownership by the funds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership without specific operational or financial performance updates from the company itself.

Positives

• Significant stake disclosed by an investment management entity, potentially indicating confidence or strategic interest in MAIA Biotechnology.
• Clear disclosure of beneficial ownership, adhering to regulatory requirements and promoting transparency.

Negatives

• The filing does not provide details on the acquisition cost or strategy behind the investment.
• The disclaimer of beneficial ownership by the underlying funds could imply a passive investment rather than active control.

Risks

• Potential for future changes in beneficial ownership, which could impact share price.
• The investment adviser's strategy could shift, leading to a sale of shares.
• Regulatory scrutiny related to beneficial ownership filings.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from MAIA Biotechnology.

Management Comments

• Solas Capital Management, LLC, which serves as the investment manager to a private fund (the "Fund") and as sub-adviser to another private fund (the "Other Fund"), which hold securities for the benefit of their investors, and Mr. Frederick Tucker Golden, as Portfolio Manager of Solas Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owners of all shares of Common Stock held by the Fund and by the Other Fund.
• Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, each of the Fund and the Other Fund expressly disclaims beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that either the Fund or the Other Fund are the beneficial owner of any of the securities reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This disclosure by Solas Capital Management, LLC indicates a notable position in MAIA Biotechnology, Inc., a company operating in the biotechnology sector, which is often characterized by high growth potential and significant research and development investment.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes, potentially influencing market perception and trading activity.
• Management of MAIA Biotechnology: Awareness of a substantial institutional investor's position.
• Regulators: Confirmation of compliance with beneficial ownership disclosure requirements.

Next Steps

• Monitor future filings from Solas Capital Management, LLC and Frederick Tucker Golden for any changes in beneficial ownership.
• Observe MAIA Biotechnology, Inc.'s operational and financial performance for insights into the strategic rationale behind this investment.

Key Dates

Keywords

MAIA Biotechnology, Schedule 13G, Solas Capital Management, Frederick Tucker Golden, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Portfolio Manager